Applied Filters
Indian court rejects AstraZeneca’s injunction request
The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
Medicure and Nexus agree Aggrastat generic licence
US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
Third Circuit under fire over FTC v AbbVie ruling
The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.
Canada's drug pricing plan prompts backlash
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Eli Lilly’s Dermira accuses Perrigo of infringing patents
Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.
Kilpatrick Townsend hires litigation team from DLA Piper
Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.
Seventh Circuit urged to review AbbVie antitrust ruling
Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.
Novartis MS drug appeal upheld in Australia
The Federal Court of Australia has backed Novartis’ appeal against a decision revoking its patent covering a multiple sclerosis drug.
Fed Circuit reinstates $235m verdict against Teva
In a victory for GlaxoSmithKline, the US Court of Appeals for the Federal Circuit has revived a 2017 jury verdict ordering Teva to pay $235 million over the drug Coreg.
Celgene, Teva execs grilled over price hikes
A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.
